Cumberland Pharmaceuticals (CPIX) Common Equity (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Common Equity across 17 years of filings, most recently posting $21.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $21.3 million, down 24.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.3 million (down 24.83% YoY), and the FY2025 annual result was $24.9 million, up 10.35% from the prior year.
• Common Equity came in at $21.3 million for Q1 2026 at Cumberland Pharmaceuticals, down from $24.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $40.8 million in Q1 2022 to a low of $21.3 million in Q1 2026.
• The 5-year median for Common Equity is $28.3 million (2025), against an average of $30.6 million.
• Across the five-year window, Common Equity plunged 31.37% in 2024 and rose 10.35% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Common Equity stood at $36.0 million in 2022, then fell by 18.66% to $29.3 million in 2023, then fell by 22.95% to $22.5 million in 2024, then gained by 10.35% to $24.9 million in 2025, then decreased by 14.38% to $21.3 million in 2026.
• The last three Common Equity figures came in at $21.3 million (Q1 2026), $24.9 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.